Event

CFA – Webinar Wednesday Feb 21 2018

Information on the Webinar hosted by Julia Alton

News

From pain to empowerment with Fabry disease

Approximately 1/12 Canadians are affected by a rare disease and prompt diagnosis is imperative as symptom management, and treatment options can drastically improve quality of life. Share the message of awareness and find what makes you rare. Maclean’s Photo Credit: Patrick Chondon http://www.macleans.ca/sponsored/from-pain-to-empowerment-with-fabry-disease/

Event

Webinar Wednesday (February 21st 2018)

Information on the Webinar hosted by Julia Alton

News

Happy Holidays!

Happy Holidays from the Canadian Fabry Association!

Event

Webinar Wednesday (January 3rd 2018)

Information on the Webinar hosted by Julia Alton

News

Replagal Approved by Health Canada

Exciting news for the CFA Community – Replagal has been approved by Health Canada as of February 2017 and all patients have been transitioned from the REP-081 study at this point. Replagal is a long-term Enzyme Replacement Therapy (ERT), the infusion will be given every 2 weeks, treatment time being approximately 4o minutes. It is […]

News

Galafold Approval

Excited to share Health Canada’s approval of the oral- precision medicine Galafold! We look forward to this differentiated treatment option for Canadian patients with amenable mutations. Please see the press release for further information.

Event

Patient Empowerment Pilot Project

Ontario Patients – Please join us for our very first Patient Empowerment Pilot Project Workshop.

News

Rare Disease Heroes – Kaye LeMoine

The CFA is honoured and proud to share this Rare Disease Hero Video featuring Kaye LeMoine….

News

Dr. West / Resverlogix and Apabetalone

In the 16-week clinical trials expected to start later this year — if the research method is given the nod by the QE II’s ethics committee — the researchers led by West and Khan will measure the effects of the drug apabetalone on 44 patients suffering with Fabry disease.